Lipozyt will develop innovative new markers that can help in personalising better and increasing the effectiveness of T2D-treatment.
Dia2-Check is designed to be a novel marker that allows to drastically cut down the diagnostic chain to effective therapy of T2D.
Dia2-Check will identify therapy–relevant subgroups for which personalised treatment-recommendations are possible.
Dia2-Check overcomes the downsides of present long-term and not personalised therapy–finding by “trial-and-error”.
Bariatric surgery (i.e. stomach surgery) proves to be highly effective with some patients (in average about 50%).
Yet, so far there exists no way to predict whether an individual patient can positively profit from this difficult surgical procedure.
Dia-Bar-Check aims to enable the break-through for bariatric surgery (i.e. stomach surgery) as a valid treatment of T2D.
For more information: “Dia-Bar-Check: A new approach”